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GlyBACKGROUND More data regarding effects of glucagon-like peptide-1 receptor agonists in patients with type 2
diabetes (T2D) and heart failure (HF) are required.
OBJECTIVES The purpose of this study was to investigate the effects of liraglutide on cardiovascular events and
mortality in LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) partici-
pants, by HF history.
METHODS In the multinational, double-blind, randomized LEADER trial, 9,340 patients with T2D and high cardiovas-
cular risk were assigned 1:1 to liraglutide (1.8 mg daily or maximum tolerated dose up to 1.8 mg daily) or placebo plus
standard care, and followed for 3.5 to 5 years. New York Heart Association (NYHA) functional class IV HF was an exclusion
criterion. The primary composite major adverse cardiovascular events outcome was time to first occurrence of cardio-
vascular death, nonfatal myocardial infarction, or nonfatal stroke. Post hoc Cox regression analyses of outcomes by
baseline HF history were conducted.
RESULTS At baseline, 18% of patients had a history of NYHA functional class I to III HF (liraglutide: n ¼ 835 of 4,668;
placebo: n ¼ 832 of 4,672). Effects of liraglutide versus placebo on major adverse cardiovascular events were consistent
in patients with (hazard ratio [HR]: 0.81 [95% confidence interval (CI): 0.65 to 1.02]) and without (HR: 0.88 [95% CI:
0.78 to 1.00]) a history of HF (p interaction ¼ 0.53). In both subgroups, fewer deaths were observed with liraglutide (HR:
0.89 [95% CI: 0.70 to 1.14] with HF; HR: 0.83 [95% CI: 0.70 to 0.97] without HF; p interaction ¼ 0.63) versus placebo.
No increased risk of HF hospitalization was observed with liraglutide, regardless of HF history (HR: 0.98 [95% CI: 0.75 to
1.28] with HF; HR: 0.78 [95% CI: 0.61 to 1.00] without HF; p interaction ¼ 0.22). Effects of liraglutide on the composite
of HF hospitalization or cardiovascular death were consistent in patients with (HR: 0.92 [95% CI: 0.74 to 1.15]) and
without (HR: 0.77 [95% CI: 0.65 to 0.91]) a history of HF (p interaction ¼ 0.19).
CONCLUSIONS Based on these findings, liraglutide should be considered suitable for patients with T2D with or without
a history of NYHA functional class I to III HF. (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular
Outcome Results [LEADER]; NCT01179048) (J Am Coll Cardiol 2020;75:1128–41) © 2020 Published by Elsevier on
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HF = heart failure
HR = hazard ratioD ifferent glucose-lowering therapies havevarying effects on heart failure (HF) out-comes. Studies of the thiazolidinediones
rosiglitazone and pioglitazone and the dipeptidyl
peptidase-4 inhibitor (DPP-4i) saxagliptin have indi-
cated an increase in the risk of HF events or HF hos-
pitalization in patients with type 2 diabetes (T2D)
(1–3), whereas the sodium-glucose cotransporter-2 in-
hibitors empagliflozin, canagliflozin, and dapagliflo-
zin reduce this risk (4–6).LVEF = left ventricular
ejection fraction
MACE = major adverse
cardiovascular events
MI = myocardial infarction
NYHA = New York Heart
Association
T2D = type 2 diabetesGlucagon-like peptide-1 receptor agonists (GLP-
1RAs) are increasingly used to treat patients with T2D
(7). Cardiovascular outcomes trials have demon-
strated the cardiovascular safety of the GLP-1RAs
lixisenatide, once-weekly exenatide, and oral sem-
aglutide (which showed noninferiority vs. placebo for
major adverse cardiovascular events [MACE]), and
cardiovascular risk reduction with liraglutide, sub-
cutaneous semaglutide, albiglutide, and dulaglutide
versus placebo in patients with T2D (8–15). Albiglu-
tide reduced the risk of HF hospitalization versus
placebo in the Harmony Outcomes trial (15); in the
remaining trials, no significant differences in risk of
HF hospitalization were reported with GLP-1RAs
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tients with HF showed improvements in left
ventricular function (16,17), others indicated
potential safety concerns in patients with HF
with reduced ejection fraction (18,19).
The LEADER (Liraglutide Effect and Action
in Diabetes: Evaluation of Cardiovascular
Outcome Results) cardiovascular outcomes
trial evaluated effects of liraglutide (1.8 mg
daily or maximum tolerated dose up to 1.8 mg
daily) versus placebo in patients with T2D
and high cardiovascular risk who were fol-
lowed for up to 5 years (12). The presence of
New York Heart Association (NYHA) func-
tional class II to III chronic HF was one of several
possible cardiovascular risk enrichment criteria and
was used to define pre-specified subgroups (12). HF
requiring hospitalization was among the adjudicated
endpoints captured during treatment exposure and
follow-up (12).
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heart rate in LEADER trial participants, stratified 
F history (NYHA functional class I to III). We also 
stigated the influence of prior atherosclerotic 
ts on risk of HF hospitalization with liraglutide 
us placebo.
HODS
design of the multinational, double-blind, 
DER cardiovascular outcomes trial 
01179048) has been detailed elsewhere (12). The 
ocol was approved by the relevant independent 
s committee or institutional review board for 
 study site. The protocol and details of the 410 
y sites have been published previously (12). All 
icipants provided written informed consent.
e LEADER trial included patients with T2D 
$50 years with either established cardiovascular 
ase or chronic kidney disease, or age $60 years 
 $1 cardiovascular risk factor. Chronic NYHA 
tional class IV HF was an exclusion criterion. HF 
ry and NYHA functional class were based on 
ical history as reported by the trial investigator 
ach patient. Information relating to inclusion/
usion criteria and to HF, including NYHA func-
l class, was recorded in a case report form at the 
ning visit.
rticipants were randomized 1:1 to receive once-
, subcutaneous liraglutide 1.8 mg (or maximum 
ated dose up to 1.8  mg) or placebo, both plus  
dard care, and followed for 3.5 to 5 years. For 
nts not meeting their glycated hemoglobin 
t, the addition of glucose-lowering medications 
permitted after randomization, except for GLP-
, DPP-4is, or pramlintide. A global expert panel 
loped standard of care treatment guidelines to 
urage investigators to manage individual partic-
t’s blood glucose, blood pressure, and lipid 
ls, and to guide concomitant therapy. Use of 
omitant medications (e.g., for management of 
iovascular risk factors and events such as HF 
italization) was at the investigator’s discretion, 
rding to local practices and regulations.
e primary endpoint was time  from  randomiza-
to the first occurrence of a composite MACE 
ome consisting of cardiovascular death, nonfatal 
uding silent) myocardial infarction (MI), or 
atal stroke. Pre-specified secondary endpoints 
ded time from randomization to the first occur-
e of: an expanded composite outcome that 
tionally included coronary revascularization or 
italization for unstable angina pectoris or HF 
anded MACE); individual components of the 



















































mposite nephropathy endpoint (new-onset macro-
buminuria, persistent doubling of serum creatinine
vel and creatinine clearance #45 ml/min/1.73 m2 per
odification of Diet in Renal Disease equation, need
r continuous renal-replacement therapy [in the
sence of an acute reversible cause], or death due to
nal disease). An external, independent, blinded
ent adjudication committee adjudicated all poten-
l cardiovascular events (including HF requiring
spitalization) and all deaths. The definitions used
r these events have been published previously (12).
e definition of adjudicated HF hospitalization is
ovided in the Online Appendix. The composite
tcomes of time to first HF hospitalization or all-
use death and of time to first HF hospitalization
cardiovascular death were analyzed post hoc.
ATISTICAL METHODS. Exploratory analyses of the
imary and secondary outcomes by chronic HF sub-
oups were pre-specified (12), but the present ana-
ses were conducted post hoc. Presence or absence
HF at screening was recorded for all randomized
rticipants (N ¼ 9,340). We evaluated the risk of
rdiovascular events, all-cause death, and ne-
ropathy observed with liraglutide versus placebo in
ADER participants with or without a history of HF
YHA functional class I to III) at baseline. The anal-
is used the full analysis set and a Cox regression
odel with treatment, HF history, and the interaction
tween these variables as covariates.
Sensitivity analyses were performed in which pa-
nts were censored at the time of first nonfatal MI/
roke (including hemorrhagic stroke) to investigate
e influence of prior atherosclerotic events on risk of
hospitalization with liraglutide versus placebo.
The interaction among trial treatment, HF history,
d heart rate was also assessed. Change in heart rate
m baseline at 3 years was analyzed using a mixed
odel for repeated measures, which included treat-
ent group (liraglutide or placebo), HF history at
seline, baseline heart rate, sex, region, antidiabetic
erapy at baseline, age at baseline, the interaction
tween each of these variables and study visit, and
e interaction between treatment group and HF
story. Statistical significance was defined as
< 0.05.
SULTS
SELINE CHARACTERISTICS. At baseline, 18% of
tients had a history of HF (NYHA functional class I
III) (12); these patients were similarly distributed
ross the two treatment groups in each NYHA func-
nal class (Table 1). Overall, most patients with HF
d NYHA functional class II HF (Table 1). Fourteen
TABLE 1 Baseline Characteristics by History of HF at Baseline and Randomized Treatment
Patients With NYHA Functional Class I–III HF
at Baseline














Male 483 (57.8) 500 (60.1) 983 (59.0) 2,528 (66.0) 2,492 (64.9) 5,020 (65.4)
Female 352 (42.2) 332 (39.9) 684 (41.0) 1,305 (34.0) 1,348 (35.1) 2,653 (34.6)
Age, yrs 63.5  7.8 64.0  7.8 63.7 (7.8) 64.4  7.1 64.5  7.1 64.4  7.1
Race
White 701 (84.0) 705 (84.7) 1,406 (84.3) 2,915 (76.1) 2,917 (76.0) 5,832 (76.0)
Black or African American 63 (7.5) 56 (6.7) 119 (7.1) 307 (8.0) 351 (9.1) 658 (8.6)
Asian 38 (4.6) 45 (5.4) 83 (5.0) 433 (11.3) 420 (10.9) 853 (11.1)
Other 33 (4.0) 26 (3.1) 59 (3.5) 178 (4.6) 152 (4.0) 330 (4.3)
Diabetes duration, yrs 11.6  7.6 11.8  8.1 11.7  7.9 13.0  8.0 13.1  8.0 13.1  8.0
Glycated hemoglobin, % 8.8  1.5 8.7  1.5 8.7  1.5 8.7  1.6 8.7  1.5 8.7  1.5
Body mass index, kg/m2 34.2  6.9 33.9  6.8 34.0  6.9 32.2  6.1 32.2  6.1 32.2  6.1
Body weight, kg 96.6  22.4 95.3  21.6 95.9  22.0 90.9  20.8 90.8  20.5 90.8  20.6
Systolic blood pressure, mm Hg 135.1  18.2 134.9  18.6 135.0  18.4 136.1  17.7 136.1  17.5 136.1  17.6
Diastolic blood pressure, mm Hg 77.2  10.6 76.9  10.2 77.1  10.4 77.2  10.3 77.0  10.1 77.1  10.2
Heart rate, beats/min 73.0  11.4 73.1  11.2 73.0  11.3 72.6  11.3 72.4  11.5 72.5  11.4
Low-density lipoprotein cholesterol, mmol/l 2.5  1.0 2.5  1.0 2.5  1.0 2.3  0.9 2.3  0.9 2.3  0.9
High-density lipoprotein cholesterol, mmol/l 1.1  0.3 1.2  0.3 1.2  0.3 1.2  0.3 1.2  0.3 1.2  0.3
Total cholesterol, mmol/l 4.6  1.2 4.6  1.3 4.6  1.2 4.4  1.2 4.4  1.1 4.4  1.2
Triglycerides, mmol/l 2.2  1.5 2.2  2.0 2.2  1.8 2.0  1.4 2.0  1.6 2.0  1.5
eGFR, ml/min/1.73 m2 78.4  26.7 77.8  26.4 78.1  26.6 80.6  27.7 81.2  27.3 80.9  27.5
Renal function
Normal (eGFR $90 ml/min/1.73 m2) 274 (32.8) 268 (32.2) 542 (32.5) 1,346 (35.1) 1,387 (36.1) 2,733 (35.6)
Mild impairment (eGFR 60 to <90 ml/min/1.73 m2) 350 (41.9) 342 (41.1) 692 (41.5) 1,582 (41.3) 1,633 (42.5) 3,215 (41.9)
Moderate impairment (eGFR 30 to <60 ml/min/1.73 m2) 186 (22.3) 201 (24.2) 387 (23.2) 813 (21.2) 734 (19.1) 1,547 (20.2)
Severe impairment (eGFR <30 ml/min/1.73 m2) 25 (3.0) 21 (2.5) 46 (2.8) 92 (2.4) 86 (2.2) 178 (2.3)
NYHA functional class*
I 179 (21.4) 169 (20.3) 348 (20.9) — — —
II 545 (65.3) 546 (65.6) 1,091 (65.4) — — —
III 108 (12.9) 106 (12.7) 214 (12.8) — — —
Unknown 3 (0.4) 11 (1.3) 14 (0.8) — — —
Values are n (%) or mean  SD. Full analysis set. *Based on medical history as reported by the trial investigator for each patient. HF includes NYHA functional class I, II, and III HF, and patients with HF at
baseline who had missing NYHA category information. Chronic NYHA functional class IV HF was a LEADER trial exclusion criterion.
eGFR ¼ estimated glomerular filtration rate (calculated using the Modification of Diet in Renal Disease formula); HF ¼ heart failure; NYHA ¼ New York Heart Association.patients with HF at baseline had missing NYHA
category information and were included in the “with
NYHA functional class I to III HF at baseline” group
(NYHA functional class IV HF was an exclusion cri-
terion) (Table 1).
Baseline characteristics were generally comparable
between treatment arms, both among patients with
andwithout a history of HF at baseline (Table 1). Higher
proportions of patients with a history of HF at baseline
were female and white, versus patients without a his-
tory of HF (Table 1). Patients with a history of HF also
had a numerically shorter mean diabetes duration and
numerically higher mean body weight, body mass in-
dex, low density lipoprotein cholesterol, and tri-
glycerides than those without HF (Table 1).
Table 2 summarizes the use of cardiovascular
medications (including angiotensin-convertingenzyme inhibitors, angiotensin receptor blockers,
beta-blockers, loop diuretic agents, and aldosterone
antagonists) at baseline by history of HF and ran-
domized treatment. The use of cardiovascular
medications was generally balanced between treat-
ment groups at baseline, with expectedly greater
use of diuretic agents and antithrombotic medica-
tion in participants with, versus without, a history
of HF at baseline (Table 2). The distribution of new
types of concomitant cardiovascular medications
added after baseline is also shown in Table 2. A
numerically higher proportion of patients with,
versus without, a history of HF at baseline initiated
new antithrombotic therapy (Table 2). There was
also slightly less initiation of new antihypertensive
and diuretic agents in participants with a history of
HF, but this may be reflective of higher baseline
use: most patients in this group were receiving
these medication classes, which can be used to treat
HF, at baseline (Table 2). Similar proportions of
patients with and without HF at baseline initiated
new loop diuretic agents (Table 2). Sodium-glucose
cotransporter-2 inhibitors had not been approved
at the time of randomization and were introduced
for relatively small proportions of patients in the
overall population (liraglutide arm: 2.1%; placebo
arm: 2.8%), as previously reported (12).
INTERACTION BETWEEN TREATMENT GROUP AND
HF HISTORY FOR CARDIOVASCULAR EVENTS AND
ALL-CAUSE DEATH. Based on pooled data for both
treatment groups, higher proportions of patients with
a history of HF at baseline experienced cardiovascular
events (except nonfatal stroke) and all-cause death
during the trial than patients without a history of HF
(Central Illustration, Table 3).
Overall, no statistically significant interaction was
detected between treatment group (liraglutide or
placebo) and HF history for cardiovascular events or
all-cause death (Central Illustration).
Effects of liraglutide versus placebo on MACE
observed in the overall population (Figure 1A) (12)
were consistent in patients with a history of HF
at baseline (Central Illustration, Figure 1B) and
those without a history of HF at baseline
(p interaction ¼ 0.53) (Central Illustration, Figure 1C).
Similar results were obtained for expanded MACE
(p interaction ¼ 0.72) (Central Illustration).
The risks of the 3 individual components of the
primary composite outcome (namely nonfatal MI,
nonfatal stroke, and cardiovascular death) in these
patient subgroups are displayed in the Central
Illustration. There was no increase in nonfatal MI or
nonfatal stroke in either subgroup (p interaction for
nonfatal MI ¼ 0.29; p interaction for nonfatal
stroke ¼ 0.99) (Central Illustration). Furthermore,
fewer patients experienced cardiovascular death with
liraglutide versus placebo, regardless of whether they
had a history of HF at baseline or not (p
interaction ¼ 0.50) (Central Illustration).
No increased risk of HF hospitalization was
observed with liraglutide versus placebo in the over-
all population (Figure 1D) (12) or in either HF subgroup
(p interaction ¼ 0.22) (Central Illustration, Figures 1E
and 1F).
Effects of liraglutide versus placebo on the com-
posite outcome of HF hospitalization or cardiovas-
cular death observed in the overall population
(Figure 1G) were consistent in patients with a
history of HF at baseline (Central Illustration,
Figure 1H) and those without HF at baseline(p interaction ¼ 0.19) (Central Illustration, Figure 1I).
Similar results were observed for all-cause death
(p interaction ¼ 0.63) (Central Illustration, Figure 2)
and for the composite outcome of HF hospitaliza-
tion or all-cause death (p interaction ¼ 0.31) (Central
Illustration).
Rates of MACE, HF hospitalization, all-cause death,
and 2 composite outcomes are presented by baseline
NYHA functional class in Table 4. Due to the small
number of patients in some of these subgroups, no
statistical analyses were performed.
INFLUENCE OF ATHEROSCLEROTIC EVENTS ON
RISK OF HF HOSPITALIZATION. In the overall pop-
ulation, there were 275 and 304 first nonfatal MI
events with liraglutide and placebo, respectively.
There were 152 and 163 first nonfatal stroke events
with liraglutide and placebo, respectively. Separate
sensitivity analyses were conducted in which patients
were censored at the time of first nonfatal MI/stroke,
to assess whether the risk of HF hospitalization with
liraglutide versus placebo was influenced by prior
atherosclerotic events. In these sensitivity analyses,
396 first events of HF hospitalization were analyzed
(compared with 466 first events of HF hospitalization
in the main analyses). Results of these analyses were
consistent with the main analyses without censoring
at the time of first nonfatal MI/stroke. Specifically, in
the overall population, the hazard ratio (HR) for lir-
aglutide versus placebo in the sensitivity analysis was
0.86 (95% confidence interval: 0.71 to 1.05). In pa-
tients with a history of HF (n ¼ 193 first events), the
corresponding HR was 0.94 (95% CI: 0.71 to 1.24) and
in those without a history of HF (n ¼ 203 first events),
it was 0.79 (95% CI: 0.60 to 1.04). Results of the main
analyses are displayed in the Central Illustration.
INTERACTION AMONG TREATMENT GROUP, HF
HISTORY, AND NEPHROPATHY. Based on estimated
glomerular filtration rate, renal function at baseline
was similar in patients with and without a history of
HF at baseline (Table 1). Incidence of the pre-specified
nephropathy endpoint was numerically lower in pa-
tients with a history of HF at baseline versus those
without HF at baseline (5.2% vs. 6.8%, respectively).
There was a significantly lower risk of nephropathy
with liraglutide versus placebo in the overall popu-
lation (12). There was no statistically significant
interaction between treatment group and history of
HF at baseline for confirmed nephropathy (p
interaction ¼ 0.95). The HR for confirmed nephropa-
thy with liraglutide versus placebo was 0.77 (95% CI:
0.51 to 1.18) in patients with a history of HF at base-
line and 0.78 (95% CI: 0.66 to 0.93) in patients
without HF at baseline.
TABLE 2 Concomitant Cardiovascular Medications by History of HF and Randomized Treatment
Patients With NYHA Functional Class I–III HF
at Baseline














Concomitant cardiovascular medications at baseline
Antihypertensive therapy 812 (97.2) 798 (95.9) 1,610 (96.6) 3,517 (91.8) 3,504 (91.3) 7,021 (91.5)
Beta-blockers 635 (76.0) 576 (69.2) 1,211 (72.6) 2,017 (52.6) 1,953 (50.9) 3,970 (51.7)
Calcium-channel blockers 260 (31.1) 244 (29.3) 504 (30.2) 1,278 (33.3) 1,235 (32.2) 2,513 (32.8)
Angiotensin-converting enzyme inhibitors 450 (53.9) 490 (58.9) 940 (56.4) 1,967 (51.3) 1,860 (48.4) 3,827 (49.9)
Angiotensin receptor blockers 278 (33.3) 231 (27.8) 509 (30.5) 1,210 (31.6) 1,255 (32.7) 2,465 (32.1)
Other antihypertensive therapies 76 (9.1) 73 (8.8) 149 (8.9) 392 (10.2) 381 (9.9) 773 (10.1)
Diuretic agents 514 (61.6) 543 (65.3) 1,057 (63.4) 1,439 (37.5) 1,410 (36.7) 2,849 (37.1)
Loop diuretic agents 328 (39.3) 334 (40.1) 662 (39.7) 496 (12.9) 503 (13.1) 999 (13.0)
Thiazides 89 (10.7) 87 (10.5) 176 (10.6) 740 (19.3) 701 (18.3) 1,441 (18.8)
Thiazide-like diuretic agents 102 (12.2) 128 (15.4) 230 (13.8) 223 (5.8) 227 (5.9) 450 (5.9)
Aldosterone antagonists 133 (15.9) 129 (15.5) 262 (15.7) 121 (3.2) 122 (3.2) 243 (3.2)
Lipid-lowering drugs 605 (72.5) 598 (71.9) 1,203 (72.2) 2,959 (77.2) 2,917 (76.0) 5,876 (76.6)
Statins 582 (69.7) 567 (68.1) 1,149 (68.9) 2,823 (73.6) 2,769 (72.1) 5,592 (72.9)
Ezetimibe 21 (2.5) 17 (2.0) 38 (2.3) 144 (3.8) 152 (4.0) 296 (3.9)
Other lipid-lowering drugs 85 (10.2) 86 (10.3) 171 (10.3) 410 (10.7) 427 (11.1) 837 (10.9)
Platelet aggregation inhibitors 550 (65.9) 520 (62.5) 1,070 (64.2) 2,655 (69.3) 2,601 (67.7) 5,256 (68.5)
Acetylsalicylic acid or acetylsalicylate lysine 517 (61.9) 494 (59.4) 1,011 (60.6) 2,460 (64.2) 2,405 (62.6) 4,865 (63.4)
Clopidogrel, ticlopidine, prasugrel, ticagrelor 105 (12.6) 101 (12.1) 206 (12.4) 615 (16.0) 644 (16.8) 1,259 (16.4)
Antithrombotic medication 130 (15.6) 123 (14.8) 253 (15.2) 179 (4.7) 191 (5.0) 370 (4.8)
Vitamin K antagonists 128 (15.3) 120 (14.4) 248 (14.9) 167 (4.4) 181 (4.7) 348 (4.5)
Direct thrombin inhibitors 2 (0.2) 3 (0.4) 5 (0.3) 15 (0.4) 9 (0.2) 24 (0.3)
Direct factor Xa inhibitors 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (<0.1) 1 (<0.1)
Cardiovascular medications initiated after baseline
Antihypertensive therapy 14 (1.7) 15 (1.8) 29 (1.7) 141 (3.7) 147 (3.8) 288 (3.8)
Beta-blockers 6 (0.7) 7 (0.8) 13 (0.8) 60 (1.6) 58 (1.5) 118 (1.5)
Calcium-channel blockers 6 (0.7) 1 (0.1) 7 (0.4) 27 (0.7) 27 (0.7) 54 (0.7)
Angiotensin-converting enzyme inhibitors 5 (0.6) 8 (1.0) 13 (0.8) 73 (1.9) 84 (2.2) 157 (2.0)
Angiotensin receptor blockers 8 (1.0) 5 (0.6) 13 (0.8) 41 (1.1) 59 (1.5) 100 (1.3)
Other antihypertensive therapies 1 (0.1) 0 (0.0) 1 (<0.1) 9 (0.2) 13 (0.3) 22 (0.3)
Diuretic agents 81 (9.7) 97 (11.7) 178 (10.7) 433 (11.3) 547 (14.2) 980 (12.8)
Loop diuretic agents 59 (7.1) 59 (7.1) 118 (7.1) 244 (6.4) 320 (8.3) 564 (7.4)
Thiazides 16 (1.9) 28 (3.4) 44 (2.6) 152 (4.0) 208 (5.4) 360 (4.7)
Thiazide-like diuretic agents 15 (1.8) 22 (2.6) 37 (2.2) 58 (1.5) 71 (1.8) 129 (1.7)
Aldosterone antagonists 26 (3.1) 29 (3.5) 55 (3.3) 91 (2.4) 64 (1.7) 155 (2.0)
Lipid-lowering drugs 76 (9.1) 89 (10.7) 165 (9.9) 332 (8.7) 389 (10.1) 721 (9.4)
Statins 64 (7.7) 79 (9.5) 143 (8.6) 306 (8.0) 368 (9.6) 674 (8.8)
Ezetimibe 3 (0.4) 3 (0.4) 6 (0.4) 14 (0.4) 11 (0.3) 25 (0.3)
Other lipid-lowering drugs 16 (1.9) 18 (2.2) 34 (2.0) 44 (1.1) 46 (1.2) 90 (1.2)
Platelet aggregation inhibitors 62 (7.4) 76 (9.1) 138 (8.3) 313 (8.2) 351 (9.1) 664 (8.7)
Acetylsalicylic acid or acetylsalicylate lysine 54 (6.5) 64 (7.7) 118 (7.1) 281 (7.3) 305 (7.9) 586 (7.6)
Clopidogrel, ticlopidine, prasugrel, ticagrelor 17 (2.0) 24 (2.9) 41 (2.5) 87 (2.3) 100 (2.6) 187 (2.4)
Antithrombotic medication 64 (7.7) 60 (7.2) 124 (7.4) 171 (4.5) 215 (5.6) 386 (5.0)
Vitamin K antagonists 49 (5.9) 47 (5.6) 96 (5.8) 124 (3.2) 142 (3.7) 266 (3.5)
Direct thrombin inhibitors 5 (0.6) 5 (0.6) 10 (0.6) 27 (0.7) 30 (0.8) 57 (0.7)
Direct factor Xa inhibitors 18 (2.2) 15 (1.8) 33 (2.0) 39 (1.0) 57 (1.5) 96 (1.3)
Values are n (%). Full analysis set. Includes patients with HF at baseline who had missing NYHA category information (n ¼ 14). Data for cardiovascular medications initiated after
baseline exclude patients who received a medication from the relevant class (antihypertensive therapy, diuretic agents, lipid-lowering drugs, platelet aggregation inhibitors, or
antithrombotic medications) at baseline.
N ¼ number of patients; NYHA ¼ New York Heart Association; % ¼ proportion of patients.
CENTRAL ILLUSTRATION Occurrence of Cardiovascular Outcomes and All-Cause Death, Stratified by History of
Heart Failure at Baseline
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   functional class I–III
No heart failure (HF)
Marso, S.P. et al. J Am Coll Cardiol. 2020;75(10):1128–41.
The p value is for the interaction between treatment group and HF at baseline. % ¼ proportion of patients with a first event between randomization and follow-up;
CI ¼ confidence interval; CV ¼ cardiovascular; HF ¼ heart failure; MACE ¼ major adverse cardiovascular events; MI ¼ myocardial infarction; N ¼ number of patients
with at least 1 event; NYHA ¼ New York Heart Association.
TABLE 3 Confirmed Deaths by History of HF at Baseline and Randomized Treatment
Patients With NYHA Functional Class
I–III HF at Baseline
Patients Without NYHA Functional Class













All-cause death 119 (14.3) 132 (15.9) 251 (15.1) 262 (6.8) 315 (8.2) 577 (7.5)
Unknown cause of death 20 (2.4) 23 (2.8) 43 (2.6) 50 (1.3) 58 (1.5) 108 (1.4)
Known cause of death 99 (11.9) 109 (13.1) 208 (12.5) 212 (5.5) 257 (6.7) 469 (6.1)
Cardiovascular 56 (6.7) 65 (7.8) 121 (7.3) 93 (2.4) 132 (3.4) 225 (2.9)
Death due to confirmed MI 5 (0.6) 7 (0.8) 12 (0.7) 12 (0.3) 19 (0.5) 31 (0.4)
Death due to confirmed stroke 5 (0.6) 7 (0.8) 12 (0.7) 10 (0.3) 18 (0.5) 28 (0.4)
Cardiovascular death not linked to a confirmed MI/stroke 46 (5.5) 51 (6.1) 97 (5.8) 71 (1.9) 95 (2.5) 166 (2.2)
Sudden cardiac death 17 (2.0) 22 (2.6) 39 (2.3) 34 (0.9) 52 (1.4) 86 (1.1)
Death due to acute MI 2 (0.2) 4 (0.5) 6 (0.4) 2 (<0.1) 11 (0.3) 13 (0.2)
Death due to HF or cardiogenic shock 15 (1.8) 18 (2.2) 33 (2.0) 10 (0.3) 13 (0.3) 23 (0.3)
Death due to cerebrovascular event 2 (0.2) 1 (0.1) 3 (0.2) 2 (<0.1) 3 (<0.1) 5 (<0.1)
Death due to other cardiovascular cause 2 (0.2) 4 (0.5) 6 (0.4) 13 (0.3) 10 (0.3) 23 (0.3)
Unclassifiable 8 (1.0) 2 (0.2) 10 (0.6) 10 (0.3) 6 (0.2) 16 (0.2)
Noncardiovascular 43 (5.1) 44 (5.3) 87 (5.2) 119 (3.1) 125 (3.3) 244 (3.2)
Values are n (%). Full analysis set. HF includes NYHA functional class I, II, and III HF, and patients with HF at baseline who had missing NYHA category information. Chronic
NYHA functional class IV HF was a LEADER trial exclusion criterion. Deaths with cause classified as “unknown” were considered cardiovascular deaths in the statistical analyses
and hence part of the cardiovascular mortality endpoint. Subclassification of cardiovascular deaths not linked to a confirmed MI/stroke was performed by the sponsor.
Abbreviations as in Table 1.INTERACTION AMONG TREATMENT GROUP, HF
HISTORY, AND HEART RATE. Liraglutide was asso-
ciated with an increase in heart rate versus placebo
in the overall population (12). No statistically sig-
nificant interaction was observed between treat-
ment group and history of HF at baseline for change
in heart rate (p interaction ¼ 0.16). The estimated
treatment difference for the change in heart rate
from baseline to 3 years was 2.3 beats/min (95% CI:
1.2 to 3.4) in patients with a history of HF at
baseline and 3.1 beats/min (95% CI: 2.6 to 3.6) in
patients without HF at baseline.
DISCUSSION
Recent European Society of Cardiology guidelines
developed in collaboration with the European Asso-
ciation for the Study of Diabetes refer to cardiovas-
cular outcome trials of glucose-lowering therapies
and provide recommendations based on their find-
ings (20). The guidelines recognize that GLP1-RAs
(liraglutide, semaglutide, lixisenatide, exenatide,
and dulaglutide) had a neutral effect on the risk of HF
hospitalization in their placebo-controlled random-
ized trials and state that these medications may be
considered for diabetes treatment in patients with HF
(20). Liraglutide is also recommended in patients
with T2D and cardiovascular disease, or very high/
high cardiovascular risk, to reduce cardiovascular
events and the risk of death (20).When considering the effect of other glucose-
lowering therapies on HF, the sodium-glucose
cotransporter-2 inhibitors empagliflozin, canagli-
flozin, and dapagliflozin have been associated with
early and significant decreases in the risk of HF out-
comes versus placebo in people with T2D (5,6,21–23).
These medications are recommended to lower the
risk of HF hospitalization in patients with diabetes
(20). In some studies, other glucose-lowering medi-
cations have been associated with an increased risk of
HF events or HF hospitalization in people with T2D
(1,3,20,24,25). For this reason, thiazolidinediones
(rosiglitazone and pioglitazone) and the DPP-4i sax-
agliptin are not recommended for diabetes treatment
in patients at risk of HF or with previous HF (20).
However, results from the TECOS (Sitagliptin
Cardiovascular Outcomes Study) and CARMELINA
(Cardiovascular and Renal Microvascular Outcome
Study With Linagliptin in Patients With Type 2
Diabetes Mellitus) cardiovascular outcomes trials
of sitagliptin and linagliptin, respectively, do not
support a class effect of DPP-4is on HF hospitaliza-
tion (26,27). Sitagliptin and linagliptin have a
neutral effect on HF hospitalization and can be
considered for diabetes treatment in patients
with HF (20). Overall, there is a need to manage
cardiovascular risk in patients with T2D in an
individualized manner.
In this study, we investigated effects of liraglutide
versus placebo on cardiovascular events, including
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Time from Randomization (Months)
4,668 4,611 4,550 4,483 4,414 4,337 4,258 4,185 1,658 467
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HR (95% CI): 0.87 (0.78; 0.97)
p < 0.001 for non-inferiority
p = 0.01 for superiority













Time from Randomization (Months)
4,668 4,593 4,496 4,400 4,280 4,172 4,072 3,982 1,562 424
4,672 4,588 4,473 4,352 4,237 4,123 4,010 3,914 1,543 407
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Time from Randomization (Months)
835 815 792 768 745 714 687 663 227 58
832 814 784 752 716 685 658 640 228 48
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Time from Randomization (Months)
3,833 3,778 3,704 3,632 3,535 3,458 3,385 3,319 1,332 366
3,840 3,773 3,689 3,600 3,521 3,438 3,352 3,274 1,314 359
Number of patients at risk
Overall Population NYHA I–III No HF
Continued on the next page
HF hospitalization, all-cause death, nephropathy, and 
heart rate, in LEADER trial participants, stratified by 
history of HF at baseline. Consistent with published 
results for the overall LEADER population (12), we 
report lower observed frequencies of MACE, 
expanded MACE, several individual cardiovascular 
endpoints, nephropathy, and death with liraglutide 
versus placebo in patients with or without a history of 
HF (NYHA functional class I to III). No increased risk 
of HF hospitalization was observed in patients ran-
domized to liraglutide versus placebo, regardless of 
baseline HF status. No statistically significant inter-
action was observed between treatment group and 
history of HF at baseline for change in heart rate. Our 
findings support the recommendation that liraglutide 
may be considered for diabetes treatment in patients 
with HF (20).
In other subgroup analyses of GLP-1RAs by history 
of HF at baseline, there were no significant differen-
tial treatment effects of lixisenatide, once-weekly 
exenatide, semaglutide, or albiglutide on MACE 
(8,9,11,13). However, reductions in all-cause death 
and the composite of all-cause death or HF hospital-
ization with once-weekly exenatide were only 
observed in patients without baseline HF (p interac-
tion for the HF subgroups ¼ 0.031 and 0.015, respec-
tively) (28).
Increases in mean heart rate (generally 
<10 beats/min) have been observed following treat-
ment with liraglutide or other GLP-1RAs (12,29,30), 
which theoretically may be detrimental in HF (31). 
No increased risk of MACE or HF hospitalization was 
observed with liraglutide versus placebo in patients 
with heart rate increases of <10 or $10 beats/min 
from baseline to 6 months in the LEADER trial (32). 
In the present analysis, the increase in heart rate 
with liraglutide did not seem to raise the risk for 
MACE or HF hospitalization, even in those patients 
with HF at baseline.
Taken together, results from previous small 
studies with liraglutide in patients with HF were 
inconclusive: some showed improvements in left 
ventricular function (16,17), while others indicated 
potential safety concerns (18,19). For example, in the 
LIVE study, which assessed 241 patients with chronicFIGURE 1 Continued
(A to C) First confirmed MACE, (D to E) HF hospitalization, and (G to I) c
(12). Copyright 2016 Massachusetts Medical Society. Reprinted with per
Kaplan-Meier method, and HRs using the Cox proportional-hazards regr
observation time beyond 54 months. CI ¼ confidence interval; CV ¼ car
events; NYHA ¼ New York Heart Association.HF with reduced left ventricular ejection fraction
(LVEF) with or without T2D, more patients experi-
enced serious cardiac adverse events in the liraglu-
tide group than in the placebo group, when serious
cardiac adverse events of different etiologies were
pooled (19). However, these events were experienced
by few patients in both treatment groups (19). The
FIGHT (Functional Impact of GLP-1 for Heart Failure
Treatment) trial, which included 300 patients with or
without T2D who were recently hospitalized with HF
and reduced LVEF, showed a nonsignificant increase
in rehospitalization for HF with liraglutide versus
placebo (18). The LIVE and FIGHT trial populations
differed from the LEADER population, which only
included patients with T2D and had a relatively low
prevalence of HF at baseline (12). Furthermore, the
LEADER population with HF (most of whom had
NYHA functional class II HF) does not represent a
more advanced HF population than the LIVE and
FIGHT populations, which recruited patients based
on LVEF criteria (#45% and #40%, respectively).
With a substantively larger dataset and much longer
treatment duration compared with LIVE and FIGHT,
the present analysis shows no increase in HF hospi-
talization with liraglutide versus placebo in patients
with a history of NYHA functional class I to III HF and
T2D.
The risk of total (first and recurrent) HF hospitali-
zation events occurring with liraglutide versus pla-
cebo in LEADER has been analyzed using 3 different
models (33). Results from each of the models were
consistent with the analysis of first HF hospitalization
events (33).
A recent meta-analysis of cardiovascular outcomes
trials showed that GLP-1RAs reduced the risk HF
hospitalization by 9%, although this reduction was
not considered statistically robust (15). It was noted
that the largest reductions in HF hospitalization were
observed in the 2 trials with the greatest reductions
in MI (Harmony Outcomes and LEADER), and hy-
pothesized that the favorable effect in the meta-
analysis could be secondary to reduction in MI (15).
However, results of our sensitivity analyses in which
patients were censored at the time of first nonfatal
MI/stroke suggest that any effect of liraglutide toomposite outcome of HF hospitalization or CV death. (A and D) Reproduced from Marso et al.
mission from Massachusetts Medical Society. Cumulative incidences estimated using the
ession model. Data analyses truncated at 54 months because <10% of patients had an
diovascular; HF ¼ heart failure; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular
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Time from Randomization (Months)
835 825 813 800 785 760 744 725 254 65
832 827 809 793 769 748 727 708 264 60
Number of patients at risk
3,833 3,816 3,786 3,758 3,720 3,685 3,638 3,597 1,465 419
3,840 3,821 3,792 3,753 3,710 3,659 3,611 3,559 1,444 405
Number of patients at risk
(A) Patients with NYHA functional class I to III HF at baseline; (B) patients without NYHA functional class I to III HF at baseline. Cumulative incidences estimated using
the Kaplan-Meier method, and HRs using the Cox proportional-hazards regression model. Data analyses truncated at 54 months because <10% of patients had an
observation time beyond 54 months. Abbreviations as in Figure 1.reduce HF hospitalization cannot be solely explained
by reductions in atherosclerotic events (nonfatal MI/
stroke).
Mechanisms underlying the observed numeric
reduction in HF hospitalization with liraglutide
versus placebo in the LEADER population are un-
known, but could involve weight loss and/or less
nephropathy with liraglutide (12). Weight reduction
from baseline was 2.3 kg (95% CI: 2.5 to 2.0) greater
with liraglutide versus placebo at 36 months (12).
Another randomized clinical trial, involving partici-
pants with obesity and clinically stable HF with pre-
served ejection fraction, showed that caloric
restriction or aerobic exercise training can lead to
weight loss and increased exercise capacity
(measured as peak oxygen consumption), represent-
ing improvement in the primary HF symptom of ex-
ercise intolerance (34). With caloric restriction,
improvements were observed in some, but not all,
measures of cardiac function, suggesting that favor-
able “noncardiac” peripheral adaptations may
accompany weight loss in these individuals (34). Inthe current analysis, liraglutide was associated with a
lower occurrence of nephropathy versus placebo in
patients with and without a history of HF at baseline.
Whether or not these results are related to the natri-
uretic effects of liraglutide (35) is unclear.
Finally, anti-inflammatory effects associated with
GLP-1RAs, including liraglutide, may also have an
impact on cardiac function and the pathophysiology
of HF (36).
STUDY LIMITATIONS AND STRENGTHS. First, it
relied on the accurate reporting of medical histories
of HF and NYHA functional class by the trial in-
vestigators at baseline. Important clinical informa-
tion related to HF, including LVEF (to confirm
reduced or preserved ejection fraction), etiology of
HF, and biomarker data (e.g. N-terminal pro-B-type
natriuretic peptide or troponin), was not collected
during the trial. As a result, some of the partici-
pants may have had undiagnosed HF, particularly if
they had a preserved ejection fraction (37). Addi-
tionally, this limitation makes it difficult to compare
the type and severity of HF observed in LEADER to
TABLE 4 Confirmed Events by NYHA Functional Class at Baseline and Randomized Treatment
Liraglutide Placebo
n % E R n % E R
No HF
Full analysis set 3,833 3,840
Patient-yrs of observation 14,763 14,707
Confirmed MACE 466 12.2 567 3.84 524 13.6 656 4.46
Confirmed HF hospitalization 110 2.9 158 1.07 140 3.6 205 1.39
All-cause death 262 6.8 262 1.77 315 8.2 315 2.14
Composite of confirmed HF hospitalization and cardiovascular death 235 6.1 301 2.04 305 7.9 395 2.69
Composite of confirmed HF hospitalization and all-cause death 348 9.1 420 2.84 417 10.9 520 3.54
NYHA functional class I HF
Full analysis set 179 169
Patient-yrs of observation 672 626
Confirmed MACE 29 16.2 33 4.91 46 27.2 57 9.10
Confirmed HF hospitalization 21 11.7 27 4.02 16 9.5 28 4.47
All-cause death 21 11.7 21 3.13 22 13.0 22 3.51
Composite of confirmed HF hospitalization and cardiovascular death 27 15.1 40 5.96 26 15.4 44 7.03
Composite of confirmed HF hospitalization and all-cause death 35 19.6 48 7.15 31 18.3 50 7.98
NYHA functional class II HF
Full analysis set 545 546
Patient-yrs of observation 1,982 1,984
Confirmed MACE 87 16.0 102 5.15 95 17.4 126 6.35
Confirmed HF hospitalization 68 12.5 127 6.41 74 13.6 125 6.30
All-cause death 80 14.7 80 4.04 88 16.1 88 4.44
Composite of confirmed HF hospitalization and cardiovascular death 102 18.7 177 8.93 112 20.5 179 9.02
Composite of confirmed HF hospitalization and all-cause death 127 23.3 207 10.44 138 25.3 213 10.74
NYHA functional class III HF
Full analysis set 108 106
Patient-yrs of observation 393 387
Confirmed MACE 25 23.1 32 8.15 24 22.6 25 6.47
Confirmed HF hospitalization 19 17.6 30 7.64 16 15.1 28 7.24
All-cause death 18 16.7 18 4.58 18 17.0 18 4.66
Composite of confirmed HF hospitalization and cardiovascular death 28 25.9 43 10.95 24 22.6 42 10.86
Composite of confirmed HF hospitalization and all-cause death 31 28.7 48 12.22 27 25.5 46 11.90
Unknown
Full analysis set 3 11
Patient-yrs of observation 12 37
Confirmed MACE 1 33.3 1 8.08 5 45.5 6 16.09
Confirmed HF hospitalization 0 0.0 0 0.00 2 18.2 3 8.05
All-cause death 0 0.0 0 0.00 4 36.4 4 10.73
Composite of confirmed HF hospitalization and cardiovascular death 0 0.0 0 0.00 5 45.5 7 18.77
Composite of confirmed HF hospitalization and all-cause death 0 0.0 0 0.00 5 45.5 7 18.77
Full analysis set. Patients with HF at baseline who had missing NYHA category information (n ¼ 14) are included in the “unknown” group.
E ¼ number of events; MACE ¼ major adverse cardiovascular events; R ¼ rate of events per 100 patient-years of observation; other abbreviations as in Tables 1 and 2.HF studied in other clinical trials. Second, this
report was based on exploratory analyses, some of
which were not pre-specified. Third, the analyses
were not corrected for multiplicity. However,
although multiple comparisons can increase the
probability of obtaining a false-positive result, no
interaction tests were statistically significant.
Fourth, the LEADER trial was not powered to detect
treatment interactions between subgroups. Fifth,our analyses may have been confounded by differ-
ences between the HF subgroups and treatment
groups (e.g., in terms of concomitant medications
received). Additionally, since LEADER included a
patient population with T2D and high cardiovascu-
lar risk (12), our findings may not be applicable to
patients with T2D who have a lower risk for car-
diovascular events than the LEADER population.
Finally, as NYHA functional class IV HF was an
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Treatment with the GLP-1
receptor agonist liraglutide is associated with favor-
able cardiovascular outcomes in patients with T2D
with or without a history of HF.
TRANSLATIONAL OUTLOOK: Further studies
should investigate the effect of GLP-1 analogs in pa-
tients with T2D and HF with reduced or preserved
ejection fractions who are well characterized with
respect to etiology and biomarkers, and clarify the
mechanisms underlying the impact on clinical
outcomes.exclusion criterion and only 13% of the HF sub-
group having NYHA functional class III HF, our
findings are mostly based on people with NYHA
functional class I and II HF, and may not be
generalizable to more advanced cases of HF. Despite
these limitations, this analysis has several
strengths, including its basis on data from a large,
multinational, double-blind cardiovascular out-
comes trial, with independent adjudication of car-
diovascular events, including HF hospitalization.
CONCLUSIONS
There was no increased risk of HF hospitalization
with liraglutide versus placebo in patients with or
without HF at baseline. Furthermore, there were
lower rates of MACE, nephropathy, and mortality
with liraglutide versus placebo, irrespective of base-
line HF status. Overall, results from this analysis of
LEADER data indicate that liraglutide should be
considered a suitable treatment option for patients
with T2D, either with or without a history of HF
(NYHA functional class I to III).
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